TOKYO, Japan and CAMBRIDGE, United Kingdom, Jan. 21, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended 31 December 2021 on Thursday, 10 February 2022.
The Company will host a webinar presentation with Shinichi Tamura, President and CEO, Chris Cargill, Chief Financial Officer, Miles Congreve, Chief Scientific Officer and Matt Barnes, Vice President, Drug Discovery at 6 pm JST (9 am GMT) on Thursday, 10 February 2022.
The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session. Please click here to pre-register, which will provide a link to access the webinar.
Presentation slides will be made available by 5 pm JST (8 am GMT) on the 10 February 2022 through the investor section of the Company’s Home Page here.
Enquiries:
Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, SVP Investor Relations and Corporate Strategy
+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
+81 (0)3 5210 3399 | IR@SoseiHeptares.com
Citigate Dewe Rogerson (for Japanese Media)
Yas Fukuda
+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com
MEDiSTRAVA Consulting (for International Media)
Mark Swallow, David Dible, Eleanor Perkin
+ 44 (0)203 928 6900| SoseiHeptares@medistrava.com
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…
CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…